Zymeworks (ZYME) Competitors $13.37 -0.40 (-2.90%) (As of 12/17/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsTrends ZYME vs. OGN, PTCT, VRNA, RYTM, MLTX, JANX, EWTX, XENE, MRUS, and ACADShould you be buying Zymeworks stock or one of its competitors? The main competitors of Zymeworks include Organon & Co. (OGN), PTC Therapeutics (PTCT), Verona Pharma (VRNA), Rhythm Pharmaceuticals (RYTM), MoonLake Immunotherapeutics (MLTX), Janux Therapeutics (JANX), Edgewise Therapeutics (EWTX), Xenon Pharmaceuticals (XENE), Merus (MRUS), and ACADIA Pharmaceuticals (ACAD). These companies are all part of the "pharmaceutical products" industry. Zymeworks vs. Organon & Co. PTC Therapeutics Verona Pharma Rhythm Pharmaceuticals MoonLake Immunotherapeutics Janux Therapeutics Edgewise Therapeutics Xenon Pharmaceuticals Merus ACADIA Pharmaceuticals Zymeworks (NYSE:ZYME) and Organon & Co. (NYSE:OGN) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their earnings, profitability, risk, valuation, media sentiment, analyst recommendations, community ranking, institutional ownership and dividends. Does the MarketBeat Community believe in ZYME or OGN? Zymeworks received 275 more outperform votes than Organon & Co. when rated by MarketBeat users. Likewise, 67.91% of users gave Zymeworks an outperform vote while only 34.00% of users gave Organon & Co. an outperform vote. CompanyUnderperformOutperformZymeworksOutperform Votes29267.91% Underperform Votes13832.09% Organon & Co.Outperform Votes1734.00% Underperform Votes3366.00% Do insiders and institutionals hold more shares of ZYME or OGN? 92.9% of Zymeworks shares are owned by institutional investors. Comparatively, 77.4% of Organon & Co. shares are owned by institutional investors. 1.9% of Zymeworks shares are owned by company insiders. Comparatively, 1.4% of Organon & Co. shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth. Do analysts recommend ZYME or OGN? Zymeworks presently has a consensus price target of $18.83, indicating a potential upside of 40.86%. Organon & Co. has a consensus price target of $21.33, indicating a potential upside of 44.44%. Given Organon & Co.'s higher probable upside, analysts clearly believe Organon & Co. is more favorable than Zymeworks.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Zymeworks 0 Sell rating(s) 2 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 2.86Organon & Co. 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 2.50 Is ZYME or OGN more profitable? Organon & Co. has a net margin of 20.30% compared to Zymeworks' net margin of -182.75%. Organon & Co.'s return on equity of 644.70% beat Zymeworks' return on equity.Company Net Margins Return on Equity Return on Assets Zymeworks-182.75% -23.00% -18.04% Organon & Co. 20.30%644.70%8.12% Which has better valuation & earnings, ZYME or OGN? Organon & Co. has higher revenue and earnings than Zymeworks. Zymeworks is trading at a lower price-to-earnings ratio than Organon & Co., indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioZymeworks$62.20M14.81-$118.67M-$1.50-8.91Organon & Co.$6.41B0.59$1.02B$5.042.93 Which has more volatility & risk, ZYME or OGN? Zymeworks has a beta of 1.12, meaning that its stock price is 12% more volatile than the S&P 500. Comparatively, Organon & Co. has a beta of 0.75, meaning that its stock price is 25% less volatile than the S&P 500. Does the media prefer ZYME or OGN? In the previous week, Zymeworks had 3 more articles in the media than Organon & Co.. MarketBeat recorded 9 mentions for Zymeworks and 6 mentions for Organon & Co.. Zymeworks' average media sentiment score of 1.29 beat Organon & Co.'s score of 0.78 indicating that Zymeworks is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Zymeworks 4 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Organon & Co. 2 Very Positive mention(s) 3 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive SummaryZymeworks beats Organon & Co. on 10 of the 18 factors compared between the two stocks. Ad Porter & CompanyA conspiracy Trump won’t unsealNew documentary reveals the lost wealth-building secret hidden deep within ancient religious texts from almost every civilization… an investment one expert says is “so perfect that only God could have created it.” Watch it now to discover how this asset that you’ve likely never considered before can produce returns so safe, secure, and endless it is nothing short of miraculous.This is the untold, true story of God’s Investment. Get Zymeworks News Delivered to You Automatically Sign up to receive the latest news and ratings for ZYME and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ZYME vs. The Competition Export to ExcelMetricZymeworksPharmaceutical IndustryMedical SectorNYSE ExchangeMarket Cap$920.90M$6.85B$5.14B$19.67BDividend YieldN/A3.06%4.81%3.51%P/E Ratio-8.9110.75135.1843.76Price / Sales14.81287.861,228.0317.39Price / CashN/A56.6540.6521.73Price / Book2.025.394.885.46Net Income-$118.67M$152.04M$118.97M$987.68M7 Day Performance2.06%-4.32%15.73%-2.32%1 Month Performance-10.33%2.80%15.69%0.63%1 Year Performance47.57%17.30%34.73%16.39% Zymeworks Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ZYMEZymeworks3.0526 of 5 stars$13.37-2.9%$18.83+40.9%+46.9%$920.90M$62.20M-8.91290Analyst UpgradePositive NewsOGNOrganon & Co.4.851 of 5 stars$14.69-4.0%$21.33+45.2%+12.9%$3.78B$6.26B2.9110,000PTCTPTC Therapeutics3.9936 of 5 stars$47.89+3.3%$54.08+12.9%+65.6%$3.69B$900.66M-8.041,410VRNAVerona Pharma1.0729 of 5 stars$42.55+2.7%$43.83+3.0%+141.2%$3.46B$460,000.00-22.2730Positive NewsRYTMRhythm Pharmaceuticals4.1309 of 5 stars$55.26+0.0%$63.70+15.3%+20.3%$3.40B$77.43M-12.76140Positive NewsMLTXMoonLake Immunotherapeutics1.7963 of 5 stars$52.20+1.7%$79.88+53.0%-7.2%$3.34BN/A-40.842News CoverageJANXJanux Therapeutics3.6007 of 5 stars$61.69+0.9%$89.90+45.7%+474.8%$3.24B$13.05M-52.2330EWTXEdgewise Therapeutics2.8314 of 5 stars$33.54+21.4%$42.33+26.2%+313.9%$3.18BN/A-22.8560Analyst ForecastShort Interest ↓News CoverageGap UpHigh Trading VolumeXENEXenon Pharmaceuticals2.7658 of 5 stars$41.20+2.9%$56.90+38.1%-0.3%$3.14B$9.43M-14.20251MRUSMerus2.9299 of 5 stars$42.89+0.1%$85.64+99.7%+77.9%$2.94B$35.93M-10.8437ACADACADIA Pharmaceuticals3.9301 of 5 stars$17.28+0.1%$25.60+48.1%-39.1%$2.88B$726.44M22.13510 Related Companies and Tools Related Companies OGN Alternatives PTCT Alternatives VRNA Alternatives RYTM Alternatives MLTX Alternatives JANX Alternatives EWTX Alternatives XENE Alternatives MRUS Alternatives ACAD Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NYSE:ZYME) was last updated on 12/18/2024 by MarketBeat.com Staff From Our PartnersTrump’s Secret Manhattan ProjectOn January 20, a whole new Manhattan Project is set to begin: Trump’s Manhattan Project. Folks, I just s...Banyan Hill Publishing | SponsoredHow this >10-cent coin is going to outperform Bitcoin Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | Sponsored Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredSeeing is believing… Today, I want to share all the details with you… and show you how to leverage this incredible wealth-building ...Porter & Company | SponsoredUncover the Top Gold Stock of the Bull MarketGold Stocks Are Surging—Is West Red Lake Gold Mines Your Next Profit Play?Huge Alerts | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowIt’s here. This is the moment we’ve been waiting for. The next 3-6 months in crypto will be absolutely life...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Zymeworks Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Zymeworks With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ZYME Stock Alerts